The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,155,697 in first-year total cost, median $577,849.
Most frequent study sections
- Special Emphasis Panel[ZDA1 GXM-A (02)]2
Most frequent institutions
- MAKSCIENTIFIC, LLC1
- NEURANO BIOSCIENCE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder2R44DA050393-02 | MOLOKANOVA, ELENA | NEURANO BIOSCIENCE, CA | $835,697 | ZDA1 |
| 2023 | Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).1R43DA057439-01 | ALAPAFUJA, SHAKIRU OLAJIRE | MAKSCIENTIFIC, LLC, MA | $320,000 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.